Incidence of tuberculosis in HIV-infected patients in Spain: The impact of treatment for LTBI

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 12, 2013, Pages

  Martinez Pino I ^a,b   Sambeat, M A ^a   Lacalle Remigio, J R ^c   Domingo, P ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Latent tuberculous infection; Treatment of latent tuberculous infection; Tuberculin skin test

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ISONIAZID; TUBERCULIN;

ADULT; AGE; ARTICLE; BACTERIUM CULTURE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPAIN; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; LATENT TUBERCULOSIS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SPAIN; TIME FACTORS; TREATMENT OUTCOME; TUBERCULIN TEST;

EID: 84888093822     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0070     Document Type: Article

References (33)

1. American Thoracic Society/Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161 (4 Pt 2): S221-S247.
2. Markowitz N, Hansen N I, Wilcosky T C, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group. Ann Intern Med 1993; 1; 119: 185-193. (Pubitemid 23327617)
3. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; 20; (1): CD000171.
4. Whalen C C, Johnson J L, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337: 801-808. (Pubitemid 27391629)
5. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-2457. (Pubitemid 28558603)
6. Halsey N A, Coberly J S, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351: 786-792. (Pubitemid 28112340)
7. Gordin F, Chaisson R E, Matts J P, et al. Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000; 283: 1445-1450.
8. Elzi L, Schlegel M, Weber R, et al. Swiss HIV Cohort Study. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44: 94-102. (Pubitemid 44968992)
9. Golub J E, Saraceni V, Cavalcante S C, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21: 1441-1448. (Pubitemid 46988004)
10. Golub J E, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23: 631-636.
11. Panel de expertos de Grupo de Estudio del Sida; Plan Nacional sobre el Sida. [2008 prevention of opportunistic infections in HIV-infected adolescents and adults guidelines. Recommendations of GESIDA/National AIDS Plan AIDS Study Group (GESIDA) and National AIDS Plan]. Enferm Infecc Microbiol Clin 2008; 26: 437-464. [Spanish]
12. Centers for Disease Control and Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1-207.
13. Working Group of the Clinical Practice Guideline on the Diagnosis, Treatment and Prevention of Tuberculosis, Centro Cochrane Iberoamericano (Iberoamerican Cochrane Centre). Clinical practice guideline on the diagnosis, treatment and prevention of tuberculosis. Quality plan for the Spanish national healthcare system of the Spanish Ministry for Health, Social Policy and Equality. CAHTA no. 2007/26. Barcelona, Spain: Agencia d'Informacio, Avaluacio i Qualitat en Salut de Catalunya, 2009.
14. Moura L C, Ximenes R A, Ramos H L, et al. An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS. BMC Public Health 2011; 11: 687.
15. Malotte C K, Rhodes F, Mais K E. Tuberculosis screening and compliance with return for skin test reading among active drug users. Am J Public Health 1998; 88: 792-796. (Pubitemid 28292053)
16. Volmink J, Garner P. Interventions for promoting adherence to tuberculosis management. Cochrane Database Syst Rev 2000; (2): CD000010.
17. Review. Update in: Cochrane Database Syst Rev 2000; (4): CD000010.
18. Diaz A, Diez M, Bleda M J, et al. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. BMC Infect Dis 2010; 10: 267.
19. Sterling T R, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh C R; Tuberculosis Epidemiologic Studies Consortium. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006; 173: 927-931.
20. Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res 2011; 133: 257-266.
21. Vitek E, Gusseinova N, Laricheva N, et al. Factors associated with positive tuberculin skin test results among HIV-infected persons in Orel Oblast, Russia. Int J Tuberc Lung Dis 2009; 13: 829-835.
22. Golub J E, Astemborski J, Ahmed M, et al. Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users. J Acquir Immune Defic Syndr 2008; 49: 532-537.
23. Levy M H, Butler T G, Zhou J. Prevalence of Mantoux positivity and annual risk of infection for tuberculosis in New South Wales prisoners, 1996 and 2001. N S W Public Health Bull 2007; 18: 119-124.
24. O'Donnell M R, Chamblee S, von Reyn C F, et al. Racial disparities in primary and reactivation tuberculosis in a rural community in the southeastern United States. Int J Tuberc Lung Dis 2010; 14: 733-740.
25. Marco A, Solé N, Orcau A, et al. Prevalence of latent tuberculosis infection in inmates recently incarcerated in a men's prison in Barcelona. Int J Tuberc Lung Dis 2012; 16: 60-64.
26. Brassard P, Hottes T S, Lalonde R G, Klein M B. Tuberculosis screening and active tuberculosis among HIV-infected persons in a Canadian tertiary care centre. Can J Infect Dis Med Microbiol 2009; 20: 51-57.
27. Gutierrez E B, Gomes V, Picone C M, Suga H, Atomiya A N. Active tuberculosis and Mycobacterium tuberculosis latent infection in patients with HIV/AIDS. HIV Med 2009; 10: 564-572.
28. Moreno S, Jarrin I, Iribarren J A, et al. Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status. Int J Tuberc Lung D is 2008; 12: 1393-1400.
29. Martín-Echevarria E, Rodríguez-Zapata M, Torralba M, et al. Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count. Int J Tuberc Lung Dis 2011; 15: 1347-1352.
30. Carosi G, Matteelli A. Prophylaxis for tuberculosis in Europe - ongoing research. Clin Infect Dis 1996; 22 (Suppl 1): S55-S60. (Pubitemid 26256459)
31. Casado J L, Moreno S, Fortún J, et al. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34: 386-389. (Pubitemid 34062241)
32. Gardner E M, McLees M P, Steiner J F, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52: 793-800.
33. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: WHO, 2011.